Business
United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall
The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l
About this update from Astrazeneca Plc
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States like California, Texas, and New York are pivotal markets, supported by healthcare advancements and telehealth adoption. Despite challenges like high treatment costs and diagnosis delays, continued investment in digital health solutions and equitable care access are expected to enhance market growth.","length":799,"tagName":"p"},{"type":"text","content":"U.S. Chronic Obstructive Pulmonary Disease (COPD) Market","length":56,"tagName":"p"},{"type":"image","alt":"U.S. Chronic Obstructive Pulmonary Disease (COPD) Market","displaySize":"","headline":null,"caption":"U.S. Chronic Obstructive Pulmonary Disease (COPD) Market","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globenewswire.com/056daae854c02d87f5354dc46353aa05"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DFuuAqMQOlwcbET60kyqtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/056daae854c02d87f5354dc46353aa05","width":600,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LohfHIFAlnu...